| 2020-01-16 |
323 |
Other Document |
asserted claims of United
States Patent No. 8,399,514 (“the ’514 patent”), on issues including invalidity…invalidity of the asserted claims of the ’514
patent, on issues including the lack of any secondary …invalidity of the asserted claims of
the ’514 patent, including the lack of any secondary considerations…United States International Trade Commission,
the Patent Trial and Appeal Board, and on matters before various…Hofmann has also been engaged by the United States Patent and Trademark
Case 1:17-cv-00116-IMK-JPM Document |
External link to document |
| 2020-01-21 |
328 |
Attachment Ex. A - proposed Reply Brief |
Term
’514 patent U.S. Patent No. 8,399,514 (issued Mar. 19, 2013)
…’s reliance on a vague citation to
the ’514 patent prosecution, IPR, and interference proceedings …30 June 2017
1:17-cv-00116-IMK-JPM
Patent - Abbreviated New Drug Applications (ANDA)
|
External link to document |
| 2020-02-08 |
358 |
Transcript |
4 Number 6. And so is this U.S. patent 8,399,514?
5 A. That is what it says on the …reading the patent
2 specification. And it was submitted both in the patent office
3… who said that in also the
5 patent office to get the patent allowed, and it's the viewpoint…artisan, thinking that the patent would not
8 work, reads the patent specification and doesn'…in the
13 patent.
14 MS. BLOODWORTH: It's not in the patent that it would |
External link to document |
| 2020-04-03 |
377 |
Response in Opposition to Motion |
stomach acid.’” Id. at 1374 (quoting U.S. Patent No. 6,926,907, a patent-in-suit). In contradiction
to this…new patent claims to the ’514 patent application, as is permitted and often happens during patent
…the PTO found Biogen’s patent claims patentable and issued the ’514
patent, and in doing so never …Multiple sclerosis
’514 patent U.S. Patent No. 8,399,514
DMF …evidence, was that Biogen’s U.S. Patent No. 8,399,514 (“the ’514 patent”) (JTX2000) lacks written
description |
External link to document |
| 2020-04-17 |
384 |
MEMORANDUM |
ABBREVIATIONS AND CONVENTIONS
ʼ514 patent U.S. Patent No. 8,399,514
asserted claims claims…Board Patent Trial and Appeal Board
PTO United States Patent and Trademark… the patent specification” in Nuvo, while “there is no corresponding teaching in the ʼ514 patent
cautioning… ʼ514 patent’s specification. To provide adequate written description for a
claim, a patent’s specification…conferred by a patent. See Ariad, 598 F.3d at 1345 (disclosure is “the quid pro quo of a
patent”).4
|
External link to document |
| 2020-06-18 |
400 |
Memorandum & Opinion |
asserted claims”) of
Biogen’s U.S. Patent No. 8,399,514 (“the ’514 Patent”) are valid
and enforceable …counterclaims, and defenses regarding U.S. Patent No. 7,619,001
(“the ’001 Patent”) until June 20, 2020 (Dkt. Nos…of the ’514 Patent
In light of these unexpected results, Biogen needed a patent
to protect…Asserted Claims of the ’514 Patent
The asserted claims in the ’514 Patent recite a method for
… evidence, that the asserted claims of the '514 Patent are invalid for lack of written description under |
External link to document |
